Vaping, SARS-CoV-2, and Multisystem Inflammatory Syndrome: A Perfect Storm

Area of Science:

• Pulmonology
• Infectious Diseases
• Adolescent Health

Background:

• Adolescent electronic cigarette (e-cigarette) use has surged, driven by flavors and social image.
• E-cigarette use impairs pulmonary defenses, increasing inflammation and fibrosis.
• Multisystem inflammatory syndrome in children (MIS-C) emerged during the SARS-CoV-2 pandemic, often with acute respiratory distress syndrome (ARDS).

Purpose of the Study:

• To explore the potential link between adolescent e-cigarette use and severe COVID-19 outcomes, specifically MIS-C.
• To investigate how vaping might exacerbate respiratory complications in adolescents infected with SARS-CoV-2.

Main Methods:

• Mini-review of existing literature on e-cigarette use, pulmonary defenses, and COVID-19.
• Analysis of the role of nicotine and ACE2 receptor upregulation in vaping-related health risks.
• Speculative analysis connecting vaping behaviors to MIS-C and ARDS in adolescents.

Main Results:

• E-cigarette use compromises lung defenses, including mucociliary clearance.
• Vaping, especially nicotine-based, upregulates angiotensin-converting enzyme 2 (ACE2) receptors, a key target for SARS-CoV-2.
• Adolescents who vape may have heightened vulnerability to severe respiratory symptoms and complications from COVID-19, including MIS-C and ARDS.

Conclusions:

• Adolescent e-cigarette users exhibit altered pulmonary defenses, making them more susceptible to SARS-CoV-2.
• Vaping may increase the risk of severe respiratory illness and ARDS in adolescents with MIS-C due to ACE2 receptor upregulation.
• Further research is needed to confirm the association and understand the mechanisms linking vaping to severe COVID-19 outcomes in adolescents.